SIRPA and colonic neoplasm: Targeting phagocytosis checkpoints such as CD47-SIRPα, CD24-Siglec-10, MHC-LILRB1, PD1-PDL1 and thereby modulating immune escape in colon cancer cells has also been demonstrated.